• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Hypothalamic expression of PD-L1: does it mediate hypothalamitis?下丘脑PD-L1的表达：它介导下丘脑炎症吗？
Cell Mol Immunol. 2019 Jun;16(6):625-626. doi: 10.1038/s41423-019-0232-2. Epub 2019 Apr 12.
2
New insight in endocrine-related adverse events associated to immune checkpoint blockade.免疫检查点阻断相关内分泌不良事件的新认识。
Best Pract Res Clin Endocrinol Metab. 2020 Jan;34(1):101370. doi: 10.1016/j.beem.2019.101370. Epub 2019 Dec 11.
3
Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors.使用免疫检查点抑制剂的癌症免疫疗法诱导的肝损伤的特征。
J Hepatol. 2018 Jun;68(6):1181-1190. doi: 10.1016/j.jhep.2018.01.033. Epub 2018 Feb 8.
4
[Strategies around PD-L1 testing in France].[法国围绕程序性死亡受体1配体（PD-L1）检测的策略]
Ann Pathol. 2017 Feb;37(1):3-4. doi: 10.1016/j.annpat.2016.11.003. Epub 2017 Jan 17.
5
The effects of checkpoint inhibition on head and neck squamous cell carcinoma: A systematic review.检查点抑制对头颈部鳞状细胞癌的影响：系统评价。
Oral Oncol. 2019 Mar;90:67-73. doi: 10.1016/j.oraloncology.2019.01.018. Epub 2019 Feb 5.
6
Atypical autoimmune adverse effects with checkpoint blockade therapies.检查点阻断疗法的非典型自身免疫不良反应。
Ann Oncol. 2017 Feb 1;28(2):206-207. doi: 10.1093/annonc/mdw658.
7
Immune Checkpoint Inhibitor-Induced Myasthenia Gravis in a Patient with Advanced NSCLC and Remote History of Thymoma.免疫检查点抑制剂诱发的重症肌无力，见于一名患有晚期非小细胞肺癌且有胸腺瘤既往史的患者。
Clin Lung Cancer. 2019 Jul;20(4):e489-e491. doi: 10.1016/j.cllc.2019.04.007. Epub 2019 Apr 19.
8
Role of immune-checkpoint inhibitors in lung cancer.免疫检查点抑制剂在肺癌中的作用。
Ther Adv Respir Dis. 2018 Jan-Dec;12:1753465817750075. doi: 10.1177/1753465817750075.
9
Pembrolizumab as second-line treatment for urothelial cancer.帕博利珠单抗作为尿路上皮癌的二线治疗药物。
Lancet Oncol. 2017 Apr;18(4):e197. doi: 10.1016/S1470-2045(17)30156-0. Epub 2017 Feb 24.
10
PD-1/PD-L1 immune checkpoint: Potential target for cancer therapy.PD-1/PD-L1 免疫检查点：癌症治疗的潜在靶点。
J Cell Physiol. 2019 Feb;234(2):1313-1325. doi: 10.1002/jcp.27172. Epub 2018 Sep 7.

引用本文的文献

1
Primary autoimmune hypothalamitis: management strategies and long-term outcomes in a tertiary care setting with a focused review of literature.原发性自身免疫性下丘脑炎：三级医疗环境中的管理策略与长期结局，并对文献进行重点综述
Endocrine. 2025 May 21. doi: 10.1007/s12020-025-04267-y.
2
Immunotherapy-Related Hypophysitis: A Narrative Review.免疫治疗相关垂体炎：一篇叙述性综述
Cancers (Basel). 2025 Jan 27;17(3):436. doi: 10.3390/cancers17030436.
3
Circulating anti-hypothalamus antibodies in celiac patients: tissue transglutaminase friend or foe?腹腔疾病患者循环中的抗下丘脑抗体：组织转谷氨酰胺酶是敌是友？
Immunol Res. 2023 Dec;71(6):839-848. doi: 10.1007/s12026-023-09394-0. Epub 2023 May 23.
4
The Uncharted Landscape of Rare Endocrine Immune-Related Adverse Events.罕见内分泌免疫相关不良事件的未知领域
Cancers (Basel). 2023 Mar 28;15(7):2016. doi: 10.3390/cancers15072016.
5
Grading Central Diabetes Insipidus Induced by Immune Checkpoint Inhibitors: A Challenging Task.免疫检查点抑制剂引起的中枢性尿崩症分级：一项具有挑战性的任务。
Front Endocrinol (Lausanne). 2022 Mar 21;13:840971. doi: 10.3389/fendo.2022.840971. eCollection 2022.
6
Immune Checkpoint Inhibitor-Induced Central Diabetes Insipidus: Looking for the Needle in the Haystack or a Very Rare Side-Effect to Promptly Diagnose?免疫检查点抑制剂诱导的中枢性尿崩症：大海捞针还是一种需及时诊断的非常罕见的副作用？
Front Oncol. 2022 Mar 3;12:798517. doi: 10.3389/fonc.2022.798517. eCollection 2022.
7
Anti-hypothalamus autoantibodies in anorexia nervosa: a possible new mechanism in neuro-physiological derangement?神经性厌食症中的抗下丘脑自身抗体：神经生理紊乱的一种新的可能机制？
Eat Weight Disord. 2022 Oct;27(7):2481-2496. doi: 10.1007/s40519-022-01388-5. Epub 2022 Mar 16.
8
Immune Checkpoint Inhibitors as a Threat to the Hypothalamus-Pituitary Axis: A Completed Puzzle.免疫检查点抑制剂对下丘脑-垂体轴的威胁：一个完整的谜题。
Cancers (Basel). 2022 Feb 18;14(4):1057. doi: 10.3390/cancers14041057.
9
Hypothalamic-Pituitary Autoimmunity in Patients Treated with Anti-PD-1 and Anti-PD-L1 Antibodies.接受抗PD-1和抗PD-L1抗体治疗患者的下丘脑-垂体自身免疫
Cancers (Basel). 2021 Aug 11;13(16):4036. doi: 10.3390/cancers13164036.

本文引用的文献

1
Hypothalamitis and severe hypothalamic dysfunction associated with anti-programmed cell death ligand 1 antibody treatment.与抗程序性细胞死亡配体1抗体治疗相关的下丘脑炎和严重下丘脑功能障碍。
Eur J Cancer. 2018 Nov;104:247-249. doi: 10.1016/j.ejca.2018.09.016. Epub 2018 Oct 28.
2
Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies.抗程序性死亡蛋白1（PD-1）和抗程序性死亡配体1（PD-L1）免疫检查点抗体的毒性
Ann Oncol. 2016 Jul;27(7):1362. doi: 10.1093/annonc/mdw141. Epub 2016 Apr 12.
3
Management of toxicities of immune checkpoint inhibitors.免疫检查点抑制剂毒性的管理。
Cancer Treat Rev. 2016 Mar;44:51-60. doi: 10.1016/j.ctrv.2016.02.001. Epub 2016 Feb 6.
4
Pituitary expression of CTLA-4 mediates hypophysitis secondary to administration of CTLA-4 blocking antibody.垂体中 CTLA-4 的表达介导 CTLA-4 阻断抗体给药引起的垂体炎。
Sci Transl Med. 2014 Apr 2;6(230):230ra45. doi: 10.1126/scitranslmed.3008002.

Hypothalamic expression of PD-L1: does it mediate hypothalamitis?

作者信息

Iervasi Erika, Strangio Antonella, Saverino Daniele

机构信息

Department of Experimental Medicine, University of Genova, Via De Toni, 14, 16132, Genova, Italy.

IRCCS Ospedale Policlinico San Martino, Largo Rosanna Benzi, 10, 16132, Genova, Italy.

出版信息

Cell Mol Immunol. 2019 Jun;16(6):625-626. doi: 10.1038/s41423-019-0232-2. Epub 2019 Apr 12.

DOI:10.1038/s41423-019-0232-2
PMID:30979971
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6804658/
Abstract
摘要